Beam Therapeutics Inc
NASDAQ:BEAM
Intrinsic Value
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. [ Read More ]
The intrinsic value of one BEAM stock under the Base Case scenario is 6.4 USD. Compared to the current market price of 22.74 USD, Beam Therapeutics Inc is Overvalued by 72%.
Valuation Backtest
Beam Therapeutics Inc
Run backtest to discover the historical profit from buying and selling BEAM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Beam Therapeutics Inc
Current Assets | 1.2B |
Cash & Short-Term Investments | 1.2B |
Other Current Assets | 21.2m |
Non-Current Assets | 248.7m |
PP&E | 237.8m |
Other Non-Current Assets | 10.9m |
Current Liabilities | 205.6m |
Accounts Payable | 1.6m |
Accrued Liabilities | 124m |
Other Current Liabilities | 80m |
Non-Current Liabilities | 272.8m |
Other Non-Current Liabilities | 272.8m |
Earnings Waterfall
Beam Therapeutics Inc
Revenue
|
377.7m
USD
|
Operating Expenses
|
-554.2m
USD
|
Operating Income
|
-176.5m
USD
|
Other Expenses
|
44m
USD
|
Net Income
|
-132.5m
USD
|
Free Cash Flow Analysis
Beam Therapeutics Inc
BEAM Profitability Score
Profitability Due Diligence
Beam Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Beam Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
BEAM Solvency Score
Solvency Due Diligence
Beam Therapeutics Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Beam Therapeutics Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BEAM Price Targets Summary
Beam Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for BEAM is 51 USD with a low forecast of 27.27 USD and a high forecast of 81.9 USD.
Ownership
BEAM Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BEAM Price
Beam Therapeutics Inc
Average Annual Return | 95.88% |
Standard Deviation of Annual Returns | 216.02% |
Max Drawdown | -87% |
Market Capitalization | 1.9B USD |
Shares Outstanding | 82 702 302 |
Percentage of Shares Shorted | 20.88% |
BEAM News
Last Important Events
Beam Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Beam Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. The company is headquartered in Cambridge, Massachusetts and currently employs 341 full-time employees. The company went IPO on 2020-02-06. The firm is focused on developing precision genetic medicines based on its base editing technology to provide life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). The Company’s base editing technology of therapeutic applications pursue a suite of both clinically validated and delivery modalities, depending on tissue type, which includes electroporation for delivery to blood cells and immune cells ex vivo; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future, and adeno-associated viral vectors (AAV), for in vivo viral delivery to the eye and potentially other organs. The firm has four development candidates, which include BEAM-101, BEAM-102, BEAM-201 and BEAM-301.
Contact
IPO
Employees
Officers
The intrinsic value of one BEAM stock under the Base Case scenario is 6.4 USD.
Compared to the current market price of 22.74 USD, Beam Therapeutics Inc is Overvalued by 72%.